The patient biotech giant came to prominence by developing treatments for rare genetic disorders, a process usually fraught with risk and expense. But in January, the company announced that it expects its 20% compound annual earnings growth to continue through 2011.
Genzyme has recently added renal, bone, and cancer treatments. A 10-year study by the American Academy of Orthopaedic Surgeons just reported good news for the company's Carticel, a cell therapy that uses a patient's own cartilage to repair damaged knees. Says Dr. Lyle Cain Jr., an orthopedic surgeon in Birmingham, Alabama: "This is the beginning of the next generation of procedures."